Insulin potentiation therapy

Last updated

Insulin potentiation therapy (IPT) is an unproven alternative cancer treatment using insulin as an adjunct to low-dose chemotherapy. It was promoted by a paper in the controversial and non-peer reviewed journal Medical Hypotheses . [1] It is not an evidence-based cancer treatment, and the costs of IPT are not covered by health insurance. [2]

Contents

According to Quackwatch, "Insulin Potentiation Therapy (IPT) is one of several unproven, dangerous treatments that is promoted by a small group of practitioners without trustworthy evidence that it works." [3]

History

It was developed by Donato Perez Garcia, MD in 1930. Originally, Garcia targeted syphilis, and later tried the treatment for chronic degenerative diseases and some types of cancer. [4]

Method

Generally, a dose of insulin is injected into a vein, followed by a much lower dose of a chemotherapy drug. [4] Then sugar water is injected to stop the hypoglycemia (low blood sugar) caused by the insulin injection. [4]

Efficacy

IPT has not been proven to work. [4] [5] Lab research indicates that there is not even a theoretical possibility of it being an effective treatment for most cancers. [2] Research over the decades has proved that most cancers grow when exposed to more insulin. [2]

One study of men with prostate cancer showed that survival was significantly shorter (11 months for men who received IPT vs 18.9 months for men on standard treatment). [2] A second small trial showed that women with metastatic breast cancer were less likely to see short-term disease progression if they received IPT with low-dose methotrexate than if they received either insulin alone or low-dose methotrexate alone. [2] (This study did not compare IPT against any of the proven multi-drug chemotherapy regimens.)

Adverse effects

The immediate risk is hypoglycemia. [4] The main risk is that the person will die from cancer because IPT does not work. [2]

The use of lower than normal doses of chemotherapy can cause drug resistance, which could make future treatment at standard, proven doses ineffective. [4] For some cancers, especially breast and colon cancers, insulin may promote tumor growth. [4]

Mechanism of action

Two main ideas about how it might work have been proposed over the years. The first idea, which has been proven wrong, is that insulin makes cells more permeable, so that the chemotherapy drugs are absorbed faster into cells. [2] The other idea is that insulin might cause the cells to start dividing, which makes them more susceptible to destruction of many cytotoxic chemotherapy drugs.[ citation needed ]

Cost

Costs run up to US$2,000 per treatment session. [4] Multiple sessions are normal. One business charges US $50,000 for the first two months. [2] Patients pay the full cost out of pocket, because it is an unproven therapy that is not covered by health insurance. [2]

See also

Related Research Articles

<span class="mw-page-title-main">Chemotherapy</span> Treatment of cancer using drugs that inhibit cell division or kill cells

Chemotherapy is a type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen. Chemotherapy may be given with a curative intent or it may aim to prolong life or to reduce symptoms. Chemotherapy is one of the major categories of the medical discipline specifically devoted to pharmacotherapy for cancer, which is called medical oncology.

Experimental cancer treatments are mainstream medical therapies intended to treat cancer by improving on, supplementing or replacing conventional methods. However, researchers are still trying to determine whether these treatments are safe and effective treatments. Experimental cancer treatments are normally available only to people who participate in formal research programs, which are called clinical trials. Occasionally, a seriously ill person may be able to access an experimental drug through an expanded access program. Some of the treatments have regulatory approval for treating other conditions. Health insurance and publicly funded health care programs normally refuse to pay for experimental cancer treatments.

<span class="mw-page-title-main">Methotrexate</span> Chemotherapy and immunosuppressant medication

Methotrexate (MTX), formerly known as amethopterin, is a chemotherapy agent and immune-system suppressant. It is used to treat cancer, autoimmune diseases, and ectopic pregnancies. Types of cancers it is used for include breast cancer, leukemia, lung cancer, lymphoma, gestational trophoblastic disease, and osteosarcoma. Types of autoimmune diseases it is used for include psoriasis, rheumatoid arthritis, and Crohn's disease. It can be given by mouth or by injection.

Hyperinsulinemic hypoglycemia describes the condition and effects of low blood glucose caused by excessive insulin. Hypoglycemia due to excess insulin is the most common type of serious hypoglycemia. It can be due to endogenous or injected insulin.

<span class="mw-page-title-main">History of cancer chemotherapy</span>

The era of cancer chemotherapy began in the 1940s with the first use of nitrogen mustards and folic acid antagonist drugs. The targeted therapy revolution has arrived, but many of the principles and limitations of chemotherapy discovered by the early researchers still apply.

Low-dose chemotherapy is being studied/used in the treatment of cancer to avoid the side effects of conventional chemotherapy. Historically, oncologists have used the highest possible dose that the body can tolerate in order to kill as many cancer cells as possible. After high-dose treatments, the body reacts, sometimes quite severely. Infections from external causes become a leading threat of death.

<span class="mw-page-title-main">Type 1 diabetes</span> Form of diabetes mellitus

Type 1 diabetes (T1D), formerly known as juvenile diabetes, is an autoimmune disease that originates when cells that make insulin are destroyed by the immune system. Insulin is a hormone required for the cells to use blood sugar for energy and it helps regulate glucose levels in the bloodstream. Before treatment this results in high blood sugar levels in the body. The common symptoms of this elevated blood sugar are frequent urination, increased thirst, increased hunger, weight loss, and other serious complications. Additional symptoms may include blurry vision, tiredness, and slow wound healing. Symptoms typically develop over a short period of time, often a matter of weeks.

Adjuvant therapy, also known as adjunct therapy, adjuvant care, or augmentation therapy, is a therapy that is given in addition to the primary or initial therapy to maximize its effectiveness. The surgeries and complex treatment regimens used in cancer therapy have led the term to be used mainly to describe adjuvant cancer treatments. An example of such adjuvant therapy is the additional treatment usually given after surgery where all detectable disease has been removed, but where there remains a statistical risk of relapse due to the presence of undetected disease. If known disease is left behind following surgery, then further treatment is not technically adjuvant.

<span class="mw-page-title-main">Alternative cancer treatments</span> Alternative or complementary treatments for cancer that have not demonstrated efficacy

Alternative cancer treatment describes any cancer treatment or practice that is not part of the conventional standard of cancer care. These include special diets and exercises, chemicals, herbs, devices, and manual procedures. Most alternative cancer treatments do not have high-quality evidence supporting their use and many have been described as fundamentally pseudoscientific. Concerns have been raised about the safety of some purported treatments and some have been found unsafe in clinical trials. Despite this, many untested and disproven treatments are used around the world. Promoting or marketing such treatments is illegal in most of the developed world.

A medical procedure is a course of action intended to achieve a result in the delivery of healthcare.

<span class="mw-page-title-main">Transitional cell carcinoma</span> Medical condition

Transitional cell carcinoma, also called urothelial carcinoma, is a type of cancer that typically occurs in the urinary system. It is the most common type of bladder cancer and cancer of the ureter, urethra, and urachus. It accounts for 95% of bladder cancer cases.

<span class="mw-page-title-main">Atrasentan</span> Chemical compound

Atrasentan is an experimental drug that is being studied for the treatment of various types of cancer, including non-small cell lung cancer. It is also being investigated as a therapy for diabetic kidney disease.

<span class="mw-page-title-main">Afatinib</span> Chemical compound

Afatinib, sold under the brand name Gilotrif among others, is a medication used to treat non-small cell lung carcinoma (NSCLC). It belongs to the tyrosine kinase inhibitor family of medications. It is taken by mouth.

Ramucirumab is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. This drug was developed by ImClone Systems Inc. It was isolated from a native phage display library from Dyax.

VAMP regimen or VAMP chemotherapy is a four-drug combination chemotherapy regimen, used today in the treatment of Hodgkin lymphoma. It was one of the earliest combination chemotherapy regimens, originally developed as a treatment for childhood leukemia by a group of researchers at the National Cancer Institute led by Emil Frei and Emil Freireich. The first clinical trial of VAMP began in 1961. Because it was the first time that four chemotherapeutic agents were used at once, the trial was highly controversial at its time. Although new combination chemotherapy regimens have replaced the use of VAMP in the treatment of childhood leukemia, VAMP is considered an important precursor to modern treatments, confirming the effectiveness of combination chemotherapy and leading to the use of combination chemotherapy regimens to treat other types of cancer.

<span class="mw-page-title-main">Min Chiu Li</span> American physician

Min Chiu Li was a Chinese-American oncologist and cancer researcher. Li was the first scientist to use chemotherapy to cure widely metastatic, malignant cancer.

<span class="mw-page-title-main">Anamorelin</span> Chemical compound

Anamorelin (INN), also known as anamorelin hydrochloride, is a non-peptide, orally-active, centrally-penetrant, selective agonist of the ghrelin/growth hormone secretagogue receptor (GHSR) with appetite-enhancing and anabolic effects which is under development by Helsinn Healthcare SA for the treatment of cancer cachexia and anorexia.

This is a historical timeline of the development and progress of cancer treatments, which includes time of discovery, progress, and approval of the treatments.

Metronomic therapy is a new type of chemotherapy in which anti-cancer drugs are administered in a lower dose than the maximum tolerated dose repetitively over a long period to treat cancers with fewer side effects. Metronomic therapy is shown to affect both tumor microenvironment and tumor cells to achieve its therapeutic effects. Metronomic therapy is also cost-effective as a lower dose is used compared to conventional chemotherapy. The use of metronomic therapy has been extensively investigated and can be advantageous in selected group of patients. Yet, more clinical trials are necessary to generalize the method.

References

  1. Ayre SG, Perez Garcia y Bellon D, Perez Garcia D (1986). "Insulin potentiation therapy: a new concept in the management of chronic degenerative disease". Med. Hypotheses. 20 (2): 199–210. doi:10.1016/0306-9877(86)90126-X. PMID   3526099.
  2. 1 2 3 4 5 6 7 8 9 Sissung, Tristan M; Schmidt, Keith T; Figg, William D (February 2019). "Insulin potentiation therapy for cancer?". The Lancet Oncology. 20 (2): 191–192. doi:10.1016/S1470-2045(19)30003-8. PMID   30712796. S2CID   73449788.
  3. Baratz, Robert (10 March 2007). "Why You Should Stay Away from Insulin Potentiation". Quackwatch. Retrieved 11 December 2012.
  4. 1 2 3 4 5 6 7 8 "Insulin potentiation therapy". CAM-Cancer. Archived from the original on 2016-03-04. Retrieved 2015-04-29.
  5. Wider, Barbara (17 May 2013). "What cancer care providers need to know about CAM: the CAM-Cancer project". Focus on Alternative and Complementary Therapies. Wiley. 18 (2): 95–100. doi:10.1111/fct.12017.

Further reading